Silexion Therapeutics Ltd.
Market Cap
$9.59K
P/E Ratio
—
EPS
—
Dividend Yield
0.00%
52-Week Range
$0.02 — $0.03
Volume
403
Avg Volume
69.59K
Beta
-0.04
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00
P/S (TTM)
0.00
P/B (TTM)
0.26
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-5.29%
ROA (TTM)
-0.65%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.07
Current Ratio
3.97
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+22.08%
EPS Growth (5Y)
+12.68%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-4.39
EPS Est (Next Year)
$-4.37
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$8.16
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
560.96K
Float
560.96K
Free Float %
100.00%
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
NASDAQ
IPO Date
2024-08-16
Employees
11
CEO
Ilan Hadar
Index Membership
—
Website
https://silexion.com
Silexion Therapeutics Ltd. (SLXNW) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $9.59K, SLXNW is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare SLXNW against other stocks using dozens of fundamental and technical filters.
No, Silexion Therapeutics Ltd. (SLXNW) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Silexion Therapeutics Ltd. (SLXNW) has a market capitalization of $9,592, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.